109 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development
8-K
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
in allergic and inflammatory diseases. Certain selected presentation materials used during the webinar are attached as Exhibit 99.1 to this Current Report
8-K
EX-99.1
h4hrn54i
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
EX-99.1
2m6i8rotivjxtms
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.1
hld0lj
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
DEFA14A
amudn5
28 Apr 23
Additional proxy soliciting materials
5:30pm
8-K
EX-10.1
al6ihaqb71edk3t0e4
27 Dec 22
Departure of Directors or Certain Officers
4:27pm
8-K
EX-3.1
fn08bgb1 4a9iw
6 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:12pm